Royalty Assignment Termination Agreement between



 Exhibit 10.24 
 ROYALTY ASSIGNMENT TERMINATION AGREEMENT 
 THIS
ROYALTY ASSIGNMENT TERMINATION AGREEMENT (this “Agreement”) is made as of November 17, 2010, by and among ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (“Accentia”), BIOVEST INTERNATIONAL, INC.,
a Delaware corporation (“Biovest”), ERATO CORP. (“Erato”), VALENS U.S. SPV I, LLC (“Valens U.S.”), VALENS OFFSHORE SPV I, LTD. (“Valens Offshore”), and PSOURCE STRUCTURED DEBT
LIMITED (“PSource” and together with Erato, Valens U.S. and Valens Offshore, the “Assignees”). 

RECITALS 
 WHEREAS, pursuant to that certain Term Loan and Security Agreement (the “Security Agreement”) dated as of November 17, 2010, by and among Biovest, the Lenders party thereto
and LV Administrative Services, Inc., the parties hereto, in consideration for the acceptance by certain of the Prepetition Lenders of the allowed secured claims against Biovest as provided therein, have agreed, among other things, to the
modification of the Biovest Royalty; 
 WHEREAS, Accentia and Biovest have entered into four
(4) separate Assignment of Rights Under Royalty Agreements, each dated as of June 18, 2008, with each of the Assignees (collectively, the “Royalty Assignment Agreements”); 

WHEREAS, pursuant to the Royalty Assignment Agreements, Accentia assigned and transferred to the Assignees,
collectively, 4.00% of the royalty of 19.50% granted to Accentia by Biovest pursuant to that certain Royalty Agreement by and between Biovest and Accentia dated as of October 31, 2006, as amended; 

WHEREAS, in order to modify the Biovest Royalty in accordance with the Security Agreement, the Royalty Assignment
Agreements must be terminated; and 
 WHEREAS, in connection with the modification of the Biovest Royalty
and pursuant to the terms and conditions of the Security Agreement and the Confirmed Plan, the parties hereto hereby desire to terminate the Royalty Assignment Agreements effective as of the date of this Agreement. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto hereby agree as follows: 
 1.        Capitalized
terms used but not defined herein shall have the meanings ascribed to them in the Security Agreement. 

2.        The parties hereto agree that the above Recitals are true and correct
in all respects. 
 3.        The parties hereto hereby consent to the
termination of the Royalty Assignment Agreements (and all of the rights and obligations created thereunder) effective as of the date of this Agreement. 

  
 -1-









 4.        Each of the Assignees
hereby acknowledges and agrees that it shall have no claims of any nature whatsoever against Biovest or Accentia as a result of the termination of the Royalty Assignment Agreements. 

5.        This Agreement shall be binding upon the parties hereto and their
respective successors and assigns. The parties hereto agree that this Agreement is fully and adequately supported by consideration, is fair and reasonable, and that they have had the opportunity to discuss this matter with counsel of their choice.
This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall be deemed to constitute one agreement. It is understood and agreed that if facsimile copies of this Agreement
bearing facsimile signatures are exchanged between the parties hereto, such copies shall in all respects have the same weight, force and legal effect and shall be fully as valid, binding, and enforceable as if such signed facsimile copies were
original documents bearing original signature. 
 6.        THIS
AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED, INTERPRETED AND ENFORCED ACCORDING TO, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS PROVISIONS THEREOF. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT SHALL BE BROUGHT ONLY IN THE STATE COURTS OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK. The prevailing party shall be entitled to recover from the other party its reasonable
attorneys’ fees and costs. Wherever possible each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under
such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

[remainder of page intentionally left blank] 







 IN WITNESS WHEREOF, the undersigned have executed this Royalty Assignment Termination
Agreement as of the date first above written. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.



			
		
	By:	 	 /s/ Samuel S.
Duffey




			
	Name:	 	Samuel S. Duffey



			
	Title:	 	President


  

			
	BIOVEST INTERNATIONAL, INC.



			
		
	By:	 	 /s/ David
Moser




			
	Name:	 	David Moser



			
	Title:	 	Secretary


  

			
	ERATO CORP.



			
		
	By:	 	 /s/ Patrick
Regan




			
	Name:	 	Patrick Regan



			
	Title:	 	Authorized Signatory


  

			
	VALENS U.S. SPV I, LLC



			
		
	By:	 	 /s/ Patrick
Regan




			
	Name:	 	Patrick Regan



			
	Title:	 	Authorized Signatory


  

			
	VALENS OFFSHORE SPV I, LTD.



			
		
	By:	 	 /s/ Patrick
Regan




			
	Name:	 	Patrick Regan



			
	Title:	 	Authorized Signatory


  

			
	PSOURCE STRUCTURED DEBT LIMITED
	By:	 	PSource Capital Ltd, It’s Investment
	Consultant


  

			
	By:	 	 /s/ Charles
Lews




			
	Name:	 	Charles Lews



			
	Title:	 	Associate Director